Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 06/02/20
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/04/20
Marinus Pharmaceuticals - Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/27/20
MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)GlobeNewsWire • 03/23/20
Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate CommunicationsGlobeNewsWire • 03/19/20
Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency DisorderGlobeNewsWire • 02/25/20
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/14/20
Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare ConferenceGlobeNewsWire • 01/07/20
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewsWire • 12/13/19
Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 12/13/19
Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private PlacementGlobeNewsWire • 12/11/19
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementGlobeNewsWire • 12/10/19
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis ComplexGlobeNewsWire • 12/09/19
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual MeetingGlobeNewsWire • 12/07/19
Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society MeetingGlobeNewsWire • 10/17/19
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus TrialGlobeNewsWire • 09/26/19